Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Omega-3 review

This article was originally published in The Tan Sheet

Executive Summary

There is "no strong evidence of reduced risk of total mortality or combined cardiovascular events in participants taking additional omega-3 fats," a systematic review of 89 studies published online by the British Medical Journal concludes. Lee Hooper, School of Medicine, University of East Anglia, Norwich, et al., analyzed 48 randomized controlled trials and 41 cohort studies and conclude there are "substantial variations" among the findings. "Neither RCTs nor cohort studies showed significantly increased risks of cancer or stroke with higher intake of omega-3, but there were too few events to rule out important events," the authors state. Current UK recommendations encouraging the general public to eat more oily fish "should continue at present, but the evidence should be reviewed regularly," Hooper et al. add. According to an accompanying editorial, "the review shows that the evidence for a reduction in cardiovascular events and mortality is less conclusive than we believed"...

You may also be interested in...

Coronavirus Update: Novartis Targets COVID-19 Cytokine Storm With Jakavi

Jakavi joins the likes of Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients

As China Rushes Medical Supplies To World, Quality Issues Resurface

As China is poised to supply globally medical products to fight coronavirus, a battle to banish its image of poor product quality is on.

UK Regulator Puts Energies Into COVID-19 While Other Services May Take Longer

With finite resources, the UK’s regulatory agency responsible for health care products is rapidly addressing COVID-19 medtech issues. But shifting its focus will cause delays elsewhere.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts